These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 29294323)

  • 1. A novel lactoferrin-modified stealth liposome for hepatoma-delivery of triiodothyronine.
    Pireddu R; Pibiri M; Valenti D; Sinico C; Fadda AM; Simbula G; Lai F
    Int J Pharm; 2018 Feb; 537(1-2):257-267. PubMed ID: 29294323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.
    Wei M; Xu Y; Zou Q; Tu L; Tang C; Xu T; Deng L; Wu C
    Eur J Pharm Sci; 2012 Jun; 46(3):131-41. PubMed ID: 22369856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma.
    Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C
    Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro targeting effect of lactoferrin modified PEGylated liposomes for hepatoma cells].
    Wei MY; Zou Q; Wu CB; Xu YH
    Yao Xue Xue Bao; 2015 Oct; 50(10):1272-9. PubMed ID: 26837173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
    Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
    Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabrication of Imatinib Mesylate-Loaded Lactoferrin-Modified PEGylated Liquid Crystalline Nanoparticles for Mitochondrial-Dependent Apoptosis in Hepatocellular Carcinoma.
    Nisha R; Kumar P; Kumar U; Mishra N; Maurya P; Singh S; Singh P; Guleria A; Saha S; Saraf SA
    Mol Pharm; 2021 Mar; 18(3):1102-1120. PubMed ID: 33356314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEGylation potentiates hepatoma cell targeted liposome-mediated in vitro gene delivery via the asialoglycoprotein receptor.
    Mkhwanazi NK; de Koning CB; van Otterlo WAL; Ariatti M; Singh M
    Z Naturforsch C J Biosci; 2017 Jul; 72(7-8):293-301. PubMed ID: 28063265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-Targeted Lactoferrin Shell-Oily Core Nanocapsules for Synergistic Targeted/Herbal Therapy of Hepatocellular Carcinoma.
    Abdelmoneem MA; Elnaggar MA; Hammady RS; Kamel SM; Helmy MW; Abdulkader MA; Zaky A; Fang JY; Elkhodairy KA; Elzoghby AO
    ACS Appl Mater Interfaces; 2019 Jul; 11(30):26731-26744. PubMed ID: 31268657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
    Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
    Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a controlled-release drug delivery system made of oleanolic acid formulated into multivesicular liposomes on hepatocellular carcinoma in vitro and in vivo.
    Luo Y; Liu Z; Zhang X; Huang J; Yu X; Li J; Xiong D; Sun X; Zhong Z
    Int J Nanomedicine; 2016; 11():3111-29. PubMed ID: 27471381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
    Liu MC; Liu L; Wang XR; Shuai WP; Hu Y; Han M; Gao JQ
    Int J Nanomedicine; 2016; 11():1395-412. PubMed ID: 27110110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma.
    Zhou X; Zhang M; Yung B; Li H; Zhou C; Lee LJ; Lee RJ
    Int J Nanomedicine; 2012; 7():5465-74. PubMed ID: 23093902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
    Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
    J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Asialoglycoprotein receptor-targeted liposomes loaded with a norcantharimide derivative for hepatocyte-selective targeting.
    Liu X; Han M; Xu J; Geng S; Zhang Y; Ye X; Gou J; Yin T; He H; Tang X
    Int J Pharm; 2017 Mar; 520(1-2):98-110. PubMed ID: 28167263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
    Kowalik MA; Puliga E; Cabras L; Sulas P; Petrelli A; Perra A; Ledda-Columbano GM; Morandi A; Merlin S; Orrù C; Sanchez-Martin C; Fornari F; Gramantieri L; Parri M; Rasola A; Bellomo SE; Sebastian C; Follenzi A; Giordano S; Columbano A
    J Hepatol; 2020 Jun; 72(6):1159-1169. PubMed ID: 31954205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice.
    Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G
    Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGD conjugated liposome-hollow silica hybrid nanovehicles for targeted and controlled delivery of arsenic trioxide against hepatic carcinoma.
    Fei W; Zhang Y; Han S; Tao J; Zheng H; Wei Y; Zhu J; Li F; Wang X
    Int J Pharm; 2017 Mar; 519(1-2):250-262. PubMed ID: 28109899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery.
    Chen H; Tang L; Qin Y; Yin Y; Tang J; Tang W; Sun X; Zhang Z; Liu J; He Q
    Eur J Pharm Sci; 2010 May; 40(2):94-102. PubMed ID: 20298779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c(RGDfK) anchored surface manipulated liposome for tumor-targeted tyrosine kinase inhibitor (TKI) delivery to potentiate liver anticancer activity.
    Deepak P; Kumar P; Arya DK; Pandey P; Kumar S; Parida BP; Narayan G; Singh S; Rajinikanth PS
    Int J Pharm; 2023 Jul; 642():123160. PubMed ID: 37379892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galactose-Modified PH-Sensitive Niosomes for Controlled Release and Hepatocellular Carcinoma Target Delivery of Tanshinone IIA.
    Hu X; Zhang J; Deng L; Hu H; Hu J; Zheng G
    AAPS PharmSciTech; 2021 Mar; 22(3):96. PubMed ID: 33694067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.